Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bio-Techne Corporation is a global life sciences company that develops, manufactures, and sells reagents, instruments, and analytical tools used in biological research, clinical diagnostics, and biopharmaceutical manufacturing. The company operates primarily within the life sciences research, biotechnology, and clinical diagnostics industries, supplying products that enable the study of proteins, genes, and cells. Its revenue is largely driven by consumable reagents and proprietary technologies that are embedded in customer workflows, supporting recurring demand.
Founded in 1976 and headquartered in North America, Bio-Techne has evolved from a niche provider of biological reagents into a diversified life sciences tools company through organic development and targeted acquisitions. The company is widely recognized for its strong brands, high-quality antibodies and proteins, and differentiated molecular and spatial biology platforms, which provide durable competitive positioning among academic, pharmaceutical, and clinical laboratory customers.
Business Operations
Bio-Techne operates through two primary business segments: Protein Sciences and Diagnostics & Genomics. The Protein Sciences segment, the company’s largest revenue contributor, includes antibodies, proteins, immunoassays, and related reagents marketed under well-established brands such as R&D Systems, Novus Biologicals, and Tocris Bioscience. These products are primarily used in academic research, drug discovery, and biopharmaceutical development.
The Diagnostics & Genomics segment focuses on molecular diagnostics, spatial biology, and gene expression analysis technologies. This segment includes advanced platforms such as Advanced Cell Diagnostics (RNAscope) and spatial biology instrumentation, generating revenue from both consumables and capital equipment. Bio-Techne operates manufacturing and R&D facilities across North America and Europe, with international sales supported by direct operations and distributors.
Strategic Position & Investments
Bio-Techne’s strategy emphasizes organic growth through innovation in high-value, differentiated technologies, complemented by selective acquisitions that expand its capabilities in fast-growing areas of biology. A key strategic focus has been spatial and single-cell biology, where the company has invested heavily to extend its RNAscope platform and integrate complementary technologies.
Notable investments include the acquisition of Advanced Cell Diagnostics, which established Bio-Techne as a leader in spatial gene expression, and Lunaphore, which expanded its footprint in spatial proteomics and high-plex tissue analysis. The company continues to invest in emerging research modalities, automation, and workflow integration to strengthen its position with pharmaceutical, biotechnology, and translational research customers.
Geographic Footprint
Bio-Techne is headquartered in North America and maintains a significant global operating presence. The company has manufacturing, research, and commercial operations across Europe, including the United Kingdom and Germany, and maintains sales and distribution capabilities in Asia-Pacific, including China and Japan.
Its products are sold worldwide to customers in over 100 countries, with international markets representing a substantial portion of total revenue. Bio-Techne’s global footprint supports close collaboration with leading research institutions and biopharmaceutical companies while providing geographic diversification and access to high-growth life sciences markets.
Leadership & Governance
Bio-Techne is led by an experienced executive team with deep expertise in life sciences, diagnostics, and operational execution. The leadership team emphasizes disciplined capital allocation, innovation-driven growth, and maintaining high standards of scientific quality and regulatory compliance.
Key executives include:
- Kim Kelderman – President & Chief Executive Officer
- Barry Siegel – Executive Vice President & Chief Financial Officer
The company operates under a shareholder-aligned governance model, with leadership focused on long-term value creation through sustained investment in technology platforms, operational excellence, and strategic acquisitions.